Quarterly ResultAug 13, 2026, 05:09 PM
PAVmed Reports Q2 Loss, Raises Going Concern Doubt
AI Summary
PAVmed Inc. reported a net loss attributable to common stockholders of $12.47 million for the six months ended June 30, 2026, a significant decline from a $4.39 million net income in the prior year. The company's management raised substantial doubt about its ability to continue as a going concern due to recurring losses and negative operating cash flows. Despite increased revenue to $55,000, operating expenses also rose, leading to an increased operating loss, though financing activities provided $7.56 million in cash.
Key Highlights
- Net loss attributable to common stockholders was $12.47 million for the six months ended June 30, 2026.
- Basic EPS was $(3.17) for the six months ended June 30, 2026, compared to $8.23 in the prior year.
- Revenue increased to $55,000 for the six months ended June 30, 2026, from $14,000 in 2025.
- Net cash used in operating activities was $5.28 million for the six months ended June 30, 2026.
- Cash and equivalents stood at $3.78 million as of June 30, 2026, up from $1.54 million at year-end 2025.
- Management expressed substantial doubt about the company's ability to continue as a going concern.
- Secured $29.91 million from Series D Preferred Stock and $15.00 million from Senior Secured Convertible Notes.
Price Impact
More from PAVM